Ischaemic Stroke in a Patient With Refractory Idiopathic Thrombocytopenic Purpura: An Unusual Clinical Dilemma

Imranullah Hashmi\textsuperscript{a,c}, Abdel Magid Bakheit\textsuperscript{b}

Abstract

Idiopathic Thrombocytopenic Purpura (ITP) is commonly associated with bleeding complications, and thrombotic events are very rare. We report a patient with long standing ITP refractory to treatment who developed a large cerebral infarct. The patient’s management was complicated by other co-morbidities, a bleeding tendency and recurrent cerebral ischaemia. A careful approach to treatment, based on the understanding of the patho-physiological mechanism of the patient’s stroke, his co-morbidity and the estimated risk of haemorrhagic complications was required in this case.

Keywords: Idiopathic thrombocytopenic purpura; Ischaemic stroke

Introduction

Idiopathic thrombocytopenic purpura (ITP) is usually associated with bleeding complications, and thrombotic events including ischaemic stroke are very rare [1-6]. The haemorrhagic manifestations of ITP include purpura, menorrhagia, epistaxis, gingival bleeding, bruising tendency, gastrointestinal haemorrhage and intracranial haemorrhage. Occasionally, ischaemic stroke is the first clinical manifestation in a previously undiagnosed case of ITP [1, 4, 6]. We report here a case of long standing ITP refractory to treatment and presenting with large ischaemic stroke. The patient also suffered from gout and other co-morbidities. These, in addition to the risk of bleeding and recurrent cerebral ischaemia, posed significant management challenges.

Case Report

A 57 year old man was admitted to hospital with severe weakness of the left side of his body, and slurring of his speech. The symptoms occurred suddenly and were preceded by a fall. Clinical examination confirmed the presence of a complete flaccid hemiplegia with facial involvement, left hemispatial neglect and mild dysarthria. There were gross deformities of both knees consistent with chronic osteoarthritis. The rest of the physical examination was entirely normal. A CT head scan was consistent with a diagnosis of a large ischaemic infarct in the territory of the right middle cerebral artery. At the time of admission to the hospital his haemoglobin was 12.9 g/dl, white cell count was 9 × 10\(^9\)/L and platelet count was 15 × 10\(^9\)/L. His liver and renal function tests were within the normal limits. He was in sinus rhythm and there were no acute changes in the ECG. His carotid Doppler scans were normal.

The patient was known to have ITP for at least 25 years which was refractory to corticosteroids and intravenous immunoglobulin therapy. His usual platelet count had been between 10 × 10\(^9\)/L and 20 × 10\(^9\)/L. Other past medical history included a myocardial infarction three years ago, hypertension and gout. He was not a smoker but had a history of excessive alcohol consumption. His regular medication was allopurinol, low dose aspirin, omeprazole, eplerinone, bisoprolol, ramipril and tramadol. Simvastatin was added on admission for the secondary prevention of stroke. Thrombolysis was not considered appropriate.

Approximately six weeks after hospital admission he developed patecheal rash all over his body and small haemorrhages on the mucosal surfaces. His platelet count at that time was less than 2 × 10\(^9\)/L. Aspirin was stopped and the blood count was monitored frequently. Four weeks later his platelet count had already improved to 16 × 10\(^9\)/L. The haemorrhages resolved and he did not have further bleeding.

A few days later he developed flare-up of gout and was...
started on non-steroidal anti-inflammatory medication. A decision was made not to restart aspirin while he was on the non-steroidal anti-inflammatory medication. However, he developed slurring of speech lasting for few hours consistent with a transient ischaemic attack (TIA). The dilemma was whether to re-start the antithrombotic treatment with aspirin. However, on weighing the risks and benefits of using aspirin for the prevention of a further stroke and of the need to continue the non-steroidal anti-inflammatory medication for pain relief and to facilitate mobilisation and physiotherapy we considered it appropriate to withhold aspirin in this case.

Discussion

ITP, an isolated thrombocytopenia of unknown cause, often results in spontaneous haemorrhage in various tissues and organs. Although intracranial haemorrhage due to ITP is rare, it is one of the most serious complications of ITP. Thrombosis is even more rare in patients with ITP and only a few cases have been previously reported [1, 4, 6-9].

The pathogenesis of intra arterial thrombosis in cases of ITP is complex. Anti-platelet antibodies, which are present in most cases of ITP, cause complement mediated fragmentation of platelets and the release of platelet microparticles (PMP). Although PMP protect against bleeding in cases of ITP, they may also promote intra vascular thrombus formation by causing platelets activation [10, 11]. The risk of thrombotic complications is also increased by the endothelial damage induced by auto-antibodies directed against antigens present on both platelets and endothelial cells [12].

Thrombotic complications may also occur after splenectomy [13] or result from some therapeutic interventions used for ITP such as treatment with intravenous immunoglobulins which increase blood viscosity, activate platelets or cause vasospasm [14]. Cases of arterial thrombosis in patients with ITP have also been reported after use of Danazol [15]. Furthermore, some patients with ITP are also susceptible to thrombotic complications because they have pro-thrombotic conditions. For example, in their prospective study Diz-kucukkaya et al [16] have found the Anti Phospholipid Syndrome in 17% of newly diagnosed patients with ITP. Occasionally, thrombotic thrombocytopenic purpura develops after ITP [17, 18].

The role of anti-platelet therapy and anticoagulation for the prevention of thrombotic complications in patients with ITP and other hypercoagulable states is not clear and the current reports provide conflicting information [1, 8, 19-21]. It has been argued that anti-platelet agents do not reduce the activity of platelet microparticles, and hence are not effective in management of such cases [6]. Consequently, the management of ischaemic stroke in patients with ITP should be individualized according to the presumed pathophysiologic mechanism of the cerebral infarct, co-morbidity, and estimated risk of haemorrhagic complications [1].

Acute ischaemic stroke requiring urgent thrombolysis is other important management dilemma. As per National Institute of Neurologic Disorders and Stroke inclusion/exclusion criteria, IV thrombolysis with tissue plasminogen activator should not be used if the platelet count is below 100 × 10^9/L. In cases of acute myocardial infarction and low platelet count due to ITP, percutaneous coronary intervention has been used [22, 23].

Conclusions

Although haemorrhage is a common complication of ITP, ischaemic stroke has been reported only rarely. The use of thrombolysis and antithrombotic drugs when ischaemic stroke occurs in a patient with ITP is controversial. In the case reported here the patient had ITP refractory to treatment and developed recurrent cerebral ischemia when aspirin was discontinued because of petechial bleeding into the skin and oral mucosa. The situation was further complicated by his need to receive regular non-steroidal anti inflammatory drugs for the symptomatic treatment of acute gout. These drugs interfere with platelet function but unlike aspirin the duration of their effect is shorter [24]. Their use therefore served a dual function - analgesia and risk reduction of intra vascular thrombosis. At the same time they posed a smaller risk (compared to aspirin) for bleeding. We conclude that the decision as to the optimal treatment regimen in cases such as the one reported here should be considered carefully and the patient’s condition should be monitored closely to avoid complications.

References


